MARKET

BIAF

BIAF

bioAffinity Tech
NASDAQ
1.990
+0.100
+5.29%
Pre Market: 1.926 -0.064 -3.24% 08:27 05/15 EDT
OPEN
1.880
PREV CLOSE
1.890
HIGH
2.000
LOW
1.870
VOLUME
2.01K
TURNOVER
0
52 WEEK HIGH
15.00
52 WEEK LOW
0.6930
MARKET CAP
9.02M
P/E (TTM)
-0.2297
1D
5D
1M
3M
1Y
5Y
1D
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
NASDAQ · 23h ago
bioAffinity CyPath Lung Test Sales Surge Sharply
TipRanks · 2d ago
BioAffinity Technologies Reports April CyPath Lung Diagnostic Unit Sales Up 300% YoY
Benzinga · 3d ago
BioAffinity says CyPath Lung test unit sales achieved monthly record in April
TipRanks · 3d ago
bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY
Benzinga · 3d ago
bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year
PUBT · 3d ago
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
Barchart · 3d ago
Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended March 31, 2026 (Form 10-Q)" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.
Press release · 4d ago
More
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAF stock methods without spending real money on the virtual paper trading platform.